Enanta Pharmaceuticals (ENTA)
Enanta Pharmaceuticals on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
2.3M
Short interest
settlement 2026-10-15
8.6
Days to cover
-0.6 days vs prior
55.2%
Short share of volume
2026-11-02
1
Fails to deliver
settlement 2026-10-02
Mon 16 Nov
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in ENTA is 2,265,069 shares, down 335,130 shares over the last month. Over the last 48 readings it ranged from 2,083,389 shares (31 December 2025) to 3,572,627 shares (14 February 2025). At the reported average volume of 264K shares a day that is 8.6 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/enta" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 2,265,069 | -11.3% | 264,255 | 8.57 |
| 2026-09-30 | 2,552,994 | -1.8% | 277,685 | 9.19 |
| 2026-09-15 | 2,600,199 | -0.6% | 242,451 | 10.72 |
| 2026-08-31 | 2,616,446 | -2.4% | 257,672 | 10.15 |
| 2026-08-14 | 2,679,755 | +3.6% | 181,762 | 14.74 |
| 2026-07-31 | 2,587,297 | +6.0% | 146,348 | 17.68 |
| 2026-07-15 | 2,441,185 | -5.5% | 191,239 | 12.77 |
| 2026-06-30 | 2,583,579 | +6.4% | 319,284 | 8.09 |
| 2026-06-15 | 2,427,371 | +6.7% | 189,612 | 12.80 |
| 2026-05-29 | 2,274,248 | +3.3% | 207,421 | 10.96 |
| 2026-05-15 | 2,202,731 | +2.2% | 235,034 | 9.37 |
| 2026-04-30 | 2,155,192 | +2.6% | 114,533 | 18.82 |
| 2026-04-15 | 2,101,431 | -1.5% | 121,515 | 17.29 |
| 2026-03-31 | 2,133,058 | -1.4% | 137,290 | 15.54 |
| 2026-03-13 | 2,163,844 | -1.1% | 192,550 | 11.24 |
| 2026-02-27 | 2,187,043 | -3.9% | 180,675 | 12.10 |
| 2026-02-13 | 2,275,475 | +0.7% | 195,576 | 11.63 |
| 2026-01-30 | 2,260,780 | +0.3% | 221,101 | 10.23 |
| 2026-01-15 | 2,255,154 | +8.2% | 266,368 | 8.47 |
| 2025-12-31 | 2,083,389 | -8.8% | 468,282 | 4.45 |
| 2025-12-15 | 2,284,705 | -7.9% | 296,022 | 7.72 |
| 2025-11-28 | 2,480,681 | -11.5% | 326,568 | 7.60 |
| 2025-11-14 | 2,803,161 | +2.5% | 297,869 | 9.41 |
| 2025-10-31 | 2,734,788 | -2.8% | 524,013 | 5.22 |
| 2025-10-15 | 2,814,736 | -16.0% | 835,768 | 3.37 |
| 2025-09-30 | 3,350,309 | +17.6% | 2,021,887 | 1.66 |
| 2025-09-15 | 2,848,661 | +0.5% | 206,730 | 13.78 |
| 2025-08-29 | 2,833,975 | -1.8% | 143,358 | 19.77 |
| 2025-08-15 | 2,884,903 | +5.6% | 144,673 | 19.94 |
| 2025-07-31 | 2,731,581 | +10.9% | 196,572 | 13.90 |
| 2025-07-15 | 2,463,124 | +1.6% | 157,567 | 15.63 |
| 2025-06-30 | 2,423,818 | -3.0% | 138,920 | 17.45 |
| 2025-06-13 | 2,498,915 | -8.2% | 237,356 | 10.53 |
| 2025-05-30 | 2,721,617 | -4.7% | 105,008 | 25.92 |
| 2025-05-15 | 2,854,687 | -3.5% | 134,930 | 21.16 |
| 2025-04-30 | 2,957,157 | +5.5% | 181,451 | 16.30 |
| 2025-04-15 | 2,803,726 | +5.1% | 315,454 | 8.89 |
| 2025-03-31 | 2,667,145 | +1.3% | 201,024 | 13.27 |
| 2025-03-14 | 2,632,482 | +1.3% | 262,336 | 10.03 |
| 2025-02-28 | 2,598,257 | -27.3% | 523,491 | 4.96 |
| 2025-02-14 | 3,572,627 | +6.2% | 603,837 | 5.92 |
| 2025-01-31 | 3,364,560 | +4.1% | 366,653 | 9.18 |
| 2025-01-15 | 3,232,743 | -3.4% | 741,016 | 4.36 |
| 2024-12-31 | 3,347,388 | -0.7% | 717,663 | 4.66 |
| 2024-12-13 | 3,371,327 | +4.3% | 575,287 | 5.86 |
| 2024-11-29 | 3,231,310 | -4.4% | 311,534 | 10.37 |
| 2024-11-15 | 3,378,684 | -1.8% | 100,767 | 33.53 |
| 2024-10-31 | 3,440,099 | +0.4% | 122,820 | 28.01 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of ENTA volume is 55.2%, up 11.4 points over the last five sessions. Over the last 30 readings it ranged from 14.9% (2 October 2026) to 66.5% (16 October 2026). The latest reading is 8.3 points above the 30-session average of 46.9%, on 110K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 61K | 110K | 55.2% | 0 |
| 2026-10-30 | 42K | 64K | 66.3% | 550 |
| 2026-10-29 | 38K | 67K | 56.6% | 130 |
| 2026-10-28 | 55K | 95K | 58.5% | 1,908 |
| 2026-10-27 | 39K | 125K | 31.5% | 0 |
| 2026-10-26 | 87K | 199K | 43.8% | 1,252 |
| 2026-10-23 | 39K | 86K | 45.3% | 0 |
| 2026-10-22 | 23K | 40K | 56.9% | 0 |
| 2026-10-21 | 20K | 46K | 42.9% | 65 |
| 2026-10-20 | 19K | 70K | 26.5% | 0 |
| 2026-10-19 | 68K | 132K | 51.5% | 0 |
| 2026-10-16 | 48K | 72K | 66.5% | 1,800 |
| 2026-10-15 | 32K | 72K | 44.1% | 0 |
| 2026-10-14 | 31K | 76K | 40.5% | 0 |
| 2026-10-13 | 26K | 61K | 42.4% | 0 |
| 2026-10-12 | 22K | 43K | 51.1% | 0 |
| 2026-10-09 | 45K | 73K | 61.6% | 0 |
| 2026-10-08 | 39K | 63K | 61.7% | 0 |
| 2026-10-07 | 32K | 86K | 37.1% | 0 |
| 2026-10-06 | 54K | 117K | 46.4% | 1,475 |
| 2026-10-05 | 37K | 73K | 50.5% | 0 |
| 2026-10-02 | 75K | 504K | 14.9% | 0 |
| 2026-10-01 | 41K | 118K | 34.4% | 4,381 |
| 2026-09-30 | 69K | 166K | 41.7% | 1,855 |
| 2026-09-29 | 71K | 143K | 49.6% | 0 |
| 2026-09-28 | 55K | 167K | 33.3% | 2,197 |
| 2026-09-25 | 45K | 89K | 50.2% | 0 |
| 2026-09-24 | 45K | 88K | 51.4% | 1,338 |
| 2026-09-23 | 50K | 91K | 55.6% | 2,098 |
| 2026-09-22 | 23K | 62K | 37.8% | 441 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 2 October 2026, the fails-to-deliver balance in ENTA is 1 share, down 5,933 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (2 October 2026) to 20,886 shares (31 October 2025). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-02 | 1 | $12.84 | $13 |
| 2026-09-23 | 5,934 | $12.42 | $74K |
| 2026-08-24 | 819 | $13.47 | $11K |
| 2026-08-11 | 14 | $13.81 | $193 |
| 2026-08-05 | 374 | $13.32 | $5K |
| 2026-07-17 | 446 | $13.19 | $6K |
| 2026-07-07 | 26 | $14.51 | $377 |
| 2026-06-25 | 33 | $13.72 | $453 |
| 2026-05-19 | 292 | $13.45 | $4K |
| 2026-05-13 | 13,090 | $14.53 | $190K |
| 2026-04-29 | 21 | $13.71 | $288 |
| 2026-04-22 | 1,600 | $13.24 | $21K |
| 2026-04-17 | 72 | $14.06 | $1K |
| 2026-04-02 | 9,000 | $12.97 | $117K |
| 2026-03-24 | 54 | $12.65 | $683 |
| 2026-03-20 | 435 | $13.00 | $6K |
| 2026-03-17 | 277 | $12.91 | $4K |
| 2026-02-18 | 375 | $13.86 | $5K |
| 2026-02-13 | 119 | $13.84 | $2K |
| 2026-02-02 | 58 | $12.90 | $748 |
| 2026-01-13 | 3 | $12.91 | $39 |
| 2026-01-07 | 37 | $13.58 | $502 |
| 2026-01-02 | 74 | $15.77 | $1K |
| 2025-12-26 | 502 | $16.60 | $8K |
| 2025-12-24 | 309 | $15.71 | $5K |
| 2025-12-22 | 3,049 | $15.39 | $47K |
| 2025-12-09 | 171 | $14.18 | $2K |
| 2025-11-18 | 573 | $12.82 | $7K |
| 2025-10-31 | 20,886 | $10.86 | $227K |
| 2025-10-24 | 378 | $10.67 | $4K |
Insider trades
SEC Form 4, newest first. JSONNo open-market insider trades were reported for ENTA in the last 90 days. The most recent filings are listed below. Latest filing: Rottinghaus Scott T. (Chief Medical Officer) on 2026-08-08.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-08-08 | Rottinghaus Scott T. | Chief Medical Officer | Tax withholding | 1K | $13.34 | $20K | 24K |
| 2026-02-12 | Kowalsky Matthew Paul | Chief Legal Officer | Tax withholding | 2K | $14.25 | $27K | 4K |
| 2026-02-12 | Kowalsky Matthew Paul | Chief Legal Officer | Grant | 4K | $0.00 | $0 | 5K |
| 2026-02-12 | Kowalsky Matthew Paul | Chief Legal Officer | Grant | 1K | $0.00 | $0 | 1K |
| 2026-02-12 | Luu Brendan | Chief Business Officer | Tax withholding | 3K | $14.25 | $46K | 42K |
| 2026-02-12 | Luu Brendan | Chief Business Officer | Grant | 5K | $0.00 | $0 | 45K |
| 2026-02-12 | Luu Brendan | Chief Business Officer | Grant | 2K | $0.00 | $0 | 40K |
| 2026-02-12 | Kieffer Tara Lynn | Chief Product Strategy Officer | Tax withholding | 3K | $14.25 | $46K | 34K |
| 2026-02-12 | Kieffer Tara Lynn | Chief Product Strategy Officer | Grant | 5K | $0.00 | $0 | 37K |
| 2026-02-12 | Kieffer Tara Lynn | Chief Product Strategy Officer | Grant | 2K | $0.00 | $0 | 32K |
| 2026-02-12 | Rottinghaus Scott T. | Chief Medical Officer | Tax withholding | 3K | $14.25 | $49K | 25K |
| 2026-02-12 | Rottinghaus Scott T. | Chief Medical Officer | Grant | 5K | $0.00 | $0 | 29K |
| 2026-02-12 | Rottinghaus Scott T. | Chief Medical Officer | Grant | 2K | $0.00 | $0 | 23K |
| 2026-02-12 | Or Yat Sun | Chief Scientific Officer | Tax withholding | 3K | $14.25 | $49K | 375K |
| 2026-02-12 | Or Yat Sun | Chief Scientific Officer | Grant | 5K | $0.00 | $0 | 378K |
| 2026-02-12 | Or Yat Sun | Chief Scientific Officer | Grant | 2K | $0.00 | $0 | 373K |
| 2026-02-12 | Luly Jay R. | President and CEO | Tax withholding | 6K | $14.25 | $88K | 872K |
| 2026-02-12 | Luly Jay R. | President and CEO | Grant | 15K | $0.00 | $0 | 878K |
| 2026-02-12 | Luly Jay R. | President and CEO | Grant | 5K | $0.00 | $0 | 863K |
| 2025-12-05 | Trout Harry R. III | See Remarks | Sell | 542 | $14.23 | $8K | 16K |
| 2025-12-05 | Rottinghaus Scott T. | Chief Medical Officer | Sell | 798 | $14.23 | $11K | 22K |
| 2025-12-05 | Luu Brendan | Chief Business Officer | Sell | 1K | $14.23 | $20K | 38K |
| 2025-12-05 | Kieffer Tara Lynn | Chief Product Strategy Officer | Sell | 2K | $14.23 | $30K | 31K |
| 2025-12-05 | Or Yat Sun | Chief Scientific Officer | Sell | 2K | $14.23 | $34K | 371K |
| 2025-12-05 | Luly Jay R. | President and CEO | Sell | 5K | $14.23 | $67K | 858K |
| 2025-12-05 | Capps Kathleen S. | See Remarks | Sell | 323 | $14.23 | $5K | 8K |
| 2025-12-02 | Trout Harry R. III | See Remarks | Sell | 380 | $13.96 | $5K | 17K |
| 2025-12-02 | Capps Kathleen S. | See Remarks | Sell | 207 | $13.96 | $3K | 9K |
| 2025-12-01 | Trout Harry R. III | See Remarks | Tax withholding | 105 | $14.12 | $1K | 17K |
| 2025-12-01 | Luu Brendan | Chief Business Officer | Tax withholding | 498 | $14.12 | $7K | 40K |
| 2025-12-01 | Kieffer Tara Lynn | Chief Product Strategy Officer | Tax withholding | 753 | $14.12 | $11K | 33K |
| 2025-12-01 | Or Yat Sun | Chief Scientific Officer | Tax withholding | 753 | $14.12 | $11K | 374K |
| 2025-12-01 | Luly Jay R. | President and CEO | Tax withholding | 2K | $14.12 | $27K | 863K |
| 2025-12-01 | Capps Kathleen S. | See Remarks | Tax withholding | 85 | $14.12 | $1K | 9K |
| 2025-11-25 | Trout Harry R. III | See Remarks | Grant | 6K | $0.00 | $0 | 17K |
| 2025-11-25 | Capps Kathleen S. | See Remarks | Grant | 3K | $0.00 | $0 | 9K |
| 2025-08-08 | Rottinghaus Scott T. | Chief Medical Officer | Tax withholding | 2K | $6.99 | $15K | 23K |
| 2025-02-12 | Luly Jay R. | President and CEO | Buy | 45K | $5.69 | $256K | 847K |
| 2025-02-12 | Luly Jay R. | President and CEO | Tax withholding | 7K | $5.59 | $42K | 865K |
| 2025-02-12 | Luly Jay R. | President and CEO | Grant | 26K | $0.00 | $0 | 872K |
| 2025-02-12 | MELLETT PAUL J | Chief Fin. & Admin Officer | Grant | 8K | $0.00 | $0 | 99K |
| 2025-02-12 | MELLETT PAUL J | Chief Fin. & Admin Officer | Tax withholding | 3K | $5.59 | $19K | 96K |
| 2025-02-12 | Or Yat Sun | Chief Scientific Officer | Grant | 10K | $0.00 | $0 | 379K |
| 2025-02-12 | Or Yat Sun | Chief Scientific Officer | Tax withholding | 4K | $5.59 | $24K | 375K |
| 2025-02-12 | Rottinghaus Scott T. | Chief Medical Officer | Tax withholding | 3K | $5.59 | $16K | 25K |
| 2025-02-12 | Rottinghaus Scott T. | Chief Medical Officer | Grant | 10K | $0.00 | $0 | 28K |
| 2025-02-12 | Kieffer Tara Lynn | Chief Product Strategy Officer | Tax withholding | 3K | $5.59 | $19K | 33K |
| 2025-02-12 | Kieffer Tara Lynn | Chief Product Strategy Officer | Grant | 8K | $0.00 | $0 | 37K |
| 2025-02-12 | Luu Brendan | Chief Business Officer | Tax withholding | 3K | $5.59 | $19K | 40K |
| 2025-02-12 | Luu Brendan | Chief Business Officer | Grant | 8K | $0.00 | $0 | 44K |
| 2024-12-06 | Luly Jay R. | President and CEO | Sell | 5K | $8.06 | $41K | 802K |
| 2024-12-06 | MELLETT PAUL J | Chief Fin. & Admin Officer | Sell | 3K | $8.06 | $21K | 92K |
| 2024-12-06 | Or Yat Sun | Chief Scientific Officer | Sell | 3K | $8.06 | $21K | 369K |
| 2024-12-06 | Rottinghaus Scott T. | Chief Medical Officer | Sell | 866 | $8.06 | $7K | 18K |
| 2024-12-06 | Luu Brendan | Chief Business Officer | Sell | 2K | $8.06 | $18K | 36K |
| 2024-12-06 | Kieffer Tara Lynn | Chief Product Strategy Officer | Sell | 2K | $8.06 | $18K | 29K |
| 2024-12-01 | Luly Jay R. | President and CEO | Tax withholding | 4K | $8.60 | $33K | 807K |
| 2024-12-01 | MELLETT PAUL J | Chief Fin. & Admin Officer | Tax withholding | 2K | $8.60 | $14K | 94K |
| 2024-12-01 | Or Yat Sun | Chief Scientific Officer | Tax withholding | 2K | $8.60 | $14K | 372K |
| 2024-12-01 | Kieffer Tara Lynn | Chief Product Strategy Officer | Tax withholding | 753 | $8.60 | $6K | 32K |
| 2024-12-01 | Luu Brendan | Chief Business Officer | Tax withholding | 753 | $8.60 | $6K | 38K |
| 2024-08-08 | Rottinghaus Scott T. | Chief Medical Officer | Tax withholding | 1K | $12.73 | $19K | 19K |
| 2024-07-15 | Rottinghaus Scott T. | Chief Medical Officer | Exercise or conversion | 5K | $8.99 | $48K | 27K |
| 2024-07-15 | Rottinghaus Scott T. | Chief Medical Officer | Sell | 5K | $17.08 | $92K | 22K |
| 2024-07-12 | Rottinghaus Scott T. | Chief Medical Officer | Sell | 2K | $15.04 | $34K | 22K |
| 2024-07-11 | Rottinghaus Scott T. | Chief Medical Officer | Sell | 4K | $15.07 | $65K | 24K |
| 2024-06-17 | Kieffer Tara Lynn | Chief Product Strategy Officer | Sell | 7K | $12.33 | $90K | 32K |
| 2024-02-26 | Gardiner Nathaniel S. | Chief Legal Officer | Exercise or conversion | 5K | $8.99 | $47K | 76K |
| 2024-02-12 | Luly Jay R. | President and CEO | Grant | 5K | $0.00 | $0 | 812K |
| 2024-02-12 | Luly Jay R. | President and CEO | Tax withholding | 2K | $12.41 | $20K | 811K |
| 2024-02-12 | MELLETT PAUL J | Chief Fin. & Admin Officer | Grant | 3K | $0.00 | $0 | 97K |
| 2024-02-12 | MELLETT PAUL J | Chief Fin. & Admin Officer | Tax withholding | 973 | $12.41 | $12K | 96K |
| 2024-02-12 | Or Yat Sun | Chief Scientific Officer | Tax withholding | 1K | $12.41 | $13K | 373K |
| 2024-02-12 | Or Yat Sun | Chief Scientific Officer | Grant | 4K | $0.00 | $0 | 374K |
| 2024-02-12 | Rottinghaus Scott T. | Chief Medical Officer | Grant | 3K | $0.00 | $0 | 29K |
| 2024-02-12 | Rottinghaus Scott T. | Chief Medical Officer | Tax withholding | 755 | $12.41 | $9K | 28K |
| 2024-02-12 | Gardiner Nathaniel S. | Chief Legal Officer | Grant | 3K | $0.00 | $0 | 71K |
| 2024-02-12 | Gardiner Nathaniel S. | Chief Legal Officer | Tax withholding | 973 | $12.41 | $12K | 71K |
| 2024-02-12 | Kieffer Tara Lynn | Chief Product Strategy Officer | Grant | 3K | $0.00 | $0 | 41K |
| 2024-02-12 | Kieffer Tara Lynn | Chief Product Strategy Officer | Tax withholding | 973 | $12.41 | $12K | 40K |
| 2024-02-12 | Luu Brendan | Chief Business Officer | Tax withholding | 973 | $12.41 | $12K | 39K |
| 2024-02-12 | Luu Brendan | Chief Business Officer | Grant | 3K | $0.00 | $0 | 40K |
| 2023-12-13 | Vance Terry | Director | Sell | 15K | $9.12 | $139K | 6K |
| 2023-12-05 | Luly Jay R. | President and CEO | Sell | 7K | $9.63 | $70K | 807K |
| 2023-12-05 | MELLETT PAUL J | Sr. VP, Finance & Admin. & CFO | Sell | 2K | $9.63 | $23K | 94K |
| 2023-12-05 | Or Yat Sun | Sr. VP, R&D & CSO | Sell | 2K | $9.63 | $23K | 371K |
| 2023-12-05 | Rottinghaus Scott T. | Sr. VP & CMO | Sell | 534 | $9.63 | $5K | 26K |
| 2023-12-05 | Gardiner Nathaniel S. | Sr. VP & General Counsel | Sell | 2K | $9.63 | $23K | 68K |
| 2023-12-05 | Kieffer Tara Lynn | Sr. VP, New Prod. Strat. & Dev | Sell | 2K | $9.63 | $20K | 37K |
| 2023-12-05 | Luu Brendan | Sr. VP, Business Dev. | Sell | 2K | $9.63 | $20K | 37K |
| 2023-12-01 | Luly Jay R. | President and CEO | Tax withholding | 6K | $9.49 | $55K | 814K |
| 2023-12-01 | MELLETT PAUL J | Sr. VP, Finance & Admin. & CFO | Tax withholding | 2K | $9.49 | $15K | 96K |
| 2023-12-01 | Or Yat Sun | Sr. VP, R&D & CSO | Tax withholding | 2K | $9.49 | $15K | 373K |
| 2023-12-01 | Gardiner Nathaniel S. | Sr. VP & General Counsel | Tax withholding | 2K | $9.49 | $15K | 71K |
| 2023-12-01 | Kieffer Tara Lynn | Sr. VP, New Prod. Strat. & Dev | Tax withholding | 753 | $9.49 | $7K | 39K |
| 2023-12-01 | Luu Brendan | Sr. VP, Business Dev. | Tax withholding | 753 | $9.49 | $7K | 39K |
| 2023-08-08 | Rottinghaus Scott T. | Chief Medical Officer | Tax withholding | 1K | $17.23 | $25K | 26K |
| 2023-04-18 | Gardiner Nathaniel S. | Sr. VP & General Counsel | Exercise or conversion | 7K | $30.00 | $200K | 80K |
| 2023-03-16 | Vance Terry | Director | Exercise or conversion | 6K | $14.00 | $81K | 21K |
| 2023-03-15 | Or Yat Sun | Sr. VP & CSO | Exercise or conversion | 14K | $14.00 | $195K | 389K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON1 Form 144 notice on file for ENTA worth $68K at the prices reported; 0 in the last 90 days worth $0. Latest: Luly Jay R. filed on 2025-12-05 to sell 4,743 shares ($68K) from 2025-12-05.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2025-12-05 | Luly Jay R.Officer, Director | 5K | $68K | 0.016% | 2025-12-05 | Morgan Stanley Smith Barney |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON19 holders report 5% or more of ENTA in their latest filing, all on Schedule 13G (passive). The largest reported stake is JANUS HENDERSON GROUP PLC at 12.1% of the class (3,494,068 shares), filed 2025-11-07 for an event on 2025-10-31.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-10-27 | 13G | BlackRock Portfolio Management LLCparent holding company | 1.6M | 5.4% | 2026-09-30 |
| 2026-08-14 | 13G/Ano. 2 | Deep Track Capital, LPinvestment adviser, other entity | 1.4M | 5.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Deep Track Biotechnology Master Fund, Ltd.corporation | 1.4M | 5.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | David Kroinparent holding company, individual | 1.4M | 5.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 8 | Gehani, Varun N.parent holding company, individual | 2.4M | 8.3% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 8 | Giauque, Nicolasparent holding company, individual | 2.4M | 8.3% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 8 | Farallon Capital Management, L.L.C.investment adviser, other entity | 2.4M | 8.3% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 8 | Wehrly, Mark C.parent holding company, individual | 2.4M | 8.3% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 8 | Warren, John R.parent holding company, individual | 2.4M | 8.3% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 8 | Spokes, Andrew J. M.parent holding company, individual | 2.4M | 8.3% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 8 | Short Daniel S.parent holding company, individual | 2.4M | 8.3% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 8 | Saito Edric C.parent holding company, individual | 2.4M | 8.3% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 8 | Roberts, Jr., Thomas G.parent holding company, individual | 2.4M | 8.3% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 8 | Luo Patrick (Cheng)parent holding company, individual | 2.4M | 8.3% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 8 | Linn, Michael G.parent holding company, individual | 2.4M | 8.3% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 8 | Kim, David T.parent holding company, individual | 2.4M | 8.3% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 8 | Husen, Avner A.parent holding company, individual | 2.4M | 8.3% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 8 | Dapice Joshua J.parent holding company, individual | 2.4M | 8.3% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 8 | Dunn Hannah E.parent holding company, individual | 2.4M | 8.3% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 8 | Dreyfuss, Philip D.parent holding company, individual | 2.4M | 8.3% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 8 | Farallon F5 (GP), L.L.C.other entity | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 8 | Farallon Institutional (GP) V, L.L.C.other entity | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 8 | Farallon Partners, L.L.C.other entity | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 8 | Farallon Capital F5 Master I, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 8 | Farallon Capital (AM) Investors, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 8 | Farallon Capital Offshore Investors II, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 8 | Four Crossings Institutional Partners V, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 8 | Farallon Capital Institutional Partners III, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 8 | Farallon Capital Institutional Partners II, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 8 | Farallon Capital Institutional Partners, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 8 | Farallon Capital Partners, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-03-26 | 13G/Ano. 6 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
| 2026-02-05 | 13G/Ano. 7 | Seybold, Williamindividual | 0 | 0.0% | 2025-12-31 |
| 2026-02-05 | 13G/Ano. 7 | Patel, Rajiv A.individual | 0 | 0.0% | 2025-12-31 |
| 2026-02-05 | 13G/Ano. 7 | Fried, Richard Bindividual | 0 | 0.0% | 2025-12-31 |
| 2026-01-20 | 13G/Ano. 2 | Integrated Core Strategies (US) LLCother entity | 666K | 2.3% | 2025-12-31 |
| 2026-01-20 | 13G/Ano. 2 | Millennium Management LLCother entity | 670K | 2.3% | 2025-12-31 |
| 2026-01-20 | 13G/Ano. 2 | Millennium Group Management LLCother entity | 670K | 2.3% | 2025-12-31 |
| 2026-01-20 | 13G/Ano. 2 | Israel A. Englanderindividual | 670K | 2.3% | 2025-12-31 |
| 2025-11-07 | 13G | JANUS HENDERSON GROUP PLCinvestment adviser, parent holding company | 3.5M | 12.1% | 2025-10-31 |
| 2025-11-07 | 13G | Janus Henderson Biotech Innovation Master Fund Ltdinvestment company | 3.0M | 10.6% | 2025-10-31 |
13F holders
Tracked managers holding ENTA at their latest 13F. JSON6 of the 30 tracked managers held ENTA at their latest 13F, $23.5M in total at quarter-end prices. Millennium Management is the largest at $9.4M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 0 added shares and 6 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Millennium Management | 2026-06-30 | 644K | $9.4M | 0.00% | -238K |
| Renaissance Technologies | 2026-06-30 | 558K | $8.1M | 0.01% | -108K |
| AQR Capital Management | 2026-06-30 | 257K | $3.7M | 0.00% | -56K |
| Two Sigma Investments | 2026-06-30 | 71K | $1.0M | 0.00% | -196K |
| Citadel Advisors | 2026-06-30 | 51K | $741K | 0.00% | -212K |
| D. E. Shaw & Co. | 2026-06-30 | 35K | $504K | 0.00% | -36K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Enanta Pharmaceuticals in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Enanta Pharmaceuticals (ENTA), SEC CIK 1177648, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-02.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2025-12-05.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-10-27.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-10.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-08-08.JSON and CSV
- Company record
- EDGAR filing index for CIK 1177648Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of ENTA is sold short?
2,265,069 shares were held short at the 2026-10-15 settlement, 8.6 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is ENTA's daily short volume?
On 2026-11-02, 60,839 of the 110,299 ENTA shares reported to FINRA were sold short, 55.2% of the day's reported volume. Short volume is a flow for one day, not a position.
Does ENTA have fails to deliver?
The SEC's latest file shows 1 ENTA shares failed to deliver at settlement 2026-10-02. Fails are reported per settlement date and published twice a month with a lag.
Are ENTA insiders buying or selling?
No open-market insider trades were reported for ENTA in the last 90 days. The most recent filings are listed below. Latest filing: Rottinghaus Scott T. (Chief Medical Officer) on 2026-08-08.
Have ENTA insiders filed to sell?
1 Form 144 notice on file for ENTA worth $68K at the prices reported; 0 in the last 90 days worth $0. Latest: Luly Jay R. filed on 2025-12-05 to sell 4,743 shares ($68K) from 2025-12-05.
Who owns 5% or more of ENTA?
19 holders report 5% or more of ENTA in their latest filing, all on Schedule 13G (passive). The largest reported stake is JANUS HENDERSON GROUP PLC at 12.1% of the class (3,494,068 shares), filed 2025-11-07 for an event on 2025-10-31.
Which tracked 13F managers own ENTA?
6 of the 30 tracked 13F managers held ENTA shares at their latest filing, $23.5M in all. The largest: Izzy Englander's Millennium Management (644K shares, $9.4M), Renaissance Technologies (558K shares, $8.1M), Cliff Asness's AQR Capital Management (257K shares, $3.7M), Two Sigma Investments (71K shares, $1.0M), Ken Griffin's Citadel Advisors (51K shares, $741K), D. E. Shaw & Co. (35K shares, $504K).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.